Patents by Inventor Derrick Arnelle

Derrick Arnelle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200383970
    Abstract: The instant application relates to morphinan derivatives of formula I with enhanced oral bioavailability for the treatment of diseases associated with opioid receptor activity or blockade including alcohol and opiate addiction.
    Type: Application
    Filed: January 10, 2020
    Publication date: December 10, 2020
    Inventors: Ryan Turncliff, Daniel Deaver, Derrick Arnelle
  • Patent number: 9775840
    Abstract: The invention relates to a compound of Formula I, II, III, IV or a pharmaceutically acceptable ester or prodrug thereof:
    Type: Grant
    Filed: July 12, 2016
    Date of Patent: October 3, 2017
    Assignee: Alkermes, Inc.
    Inventors: Laura Cook Blumberg, Derrick Arnelle
  • Publication number: 20170112827
    Abstract: The instant application relates to morphinan derivatives of formula I with enhanced oral bioavailability for the treatment of diseases associated with opioid receptor activity or blockade including alcohol and opiate addiction.
    Type: Application
    Filed: November 17, 2016
    Publication date: April 27, 2017
    Inventors: Ryan Turncliff, Daniel Deaver, Derrick Arnelle
  • Publication number: 20170042882
    Abstract: The present invention relates to compounds of Formula I or II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which relates to mophinan compounds useful as ?, ? and/or ? receptor opioid compounds and pharmaceuticals containing same that may be useful for mediating analgesia, combating drug addiction, alcohol addiction, drug overdose, mental illness, bladder dysfunctions, neurogenic bladder, interstitial cystitis, urinary incontinence, premature ejaculation, inflammatory pain, peripherally mediated and neuropathic pain, cough, lung edema, diarrhea, cardiac disorders, cardioprotection, depression, and cognitive, respiratory, diarrhea, irritable bowel syndrome and gastro-intestinal disorders, immunomodulation, and anti-tumor agents.
    Type: Application
    Filed: August 17, 2016
    Publication date: February 16, 2017
    Inventors: Derrick Arnelle, Daniel Deaver, Reginald L. Dean, III, Mark Todtenkopf
  • Publication number: 20170007609
    Abstract: The invention relates to a compound of Formula I, II, III, IV or a pharmaceutically acceptable ester or prodrug thereof:
    Type: Application
    Filed: July 12, 2016
    Publication date: January 12, 2017
    Inventors: Laura Cook Blumberg, Derrick Arnelle
  • Patent number: 9415045
    Abstract: The invention relates to a compound of Formula I, II, III, IV or a pharmaceutically acceptable ester or prodrug thereof:
    Type: Grant
    Filed: January 16, 2015
    Date of Patent: August 16, 2016
    Assignee: Alkermes, Inc.
    Inventors: Laura Cook Blumberg, Derrick Arnelle
  • Publication number: 20160082004
    Abstract: The present invention relates to compounds of Formula I or II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which relates to morphinan compounds useful as ?, ? and/or ? receptor opioid compounds and pharmaceuticals containing same that may be useful for mediating analgesia, combating drug addiction, alcohol addiction, drug overdose, mental illness, bladder dysfunctions, neurogenic bladder, interstitial cystitis, urinary incontinence, premature ejaculation, inflammatory pain, peripherally mediated and neuropathic pain, cough, lung edema, diarrhea, cardiac disorders, cardioprotection, depression, and cognitive, respiratory, diarrhea, irritable bowel syndrome and gastro-intestinal disorders, immunomodulation, and anti-tumor agents.
    Type: Application
    Filed: April 24, 2015
    Publication date: March 24, 2016
    Inventors: Derrick Arnelle, Daniel Deaver, Reginald L. Dean, III, Mark Todtenkopf
  • Publication number: 20150196550
    Abstract: The invention relates to a compound of Formula I, II, III, IV or a pharmaceutically acceptable ester or prodrug thereof:
    Type: Application
    Filed: January 16, 2015
    Publication date: July 16, 2015
    Inventors: Laura Cook Blumberg, Derrick Arnelle
  • Patent number: 9040552
    Abstract: The present invention relates to compounds of Formula I or II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which relates to mophinan compounds useful as ?, ? and/or ? receptor opioid compounds and pharmaceuticals containing same that may be useful for mediating analgesia, combating drug addiction, alcohol addiction, drug overdose, mental illness, bladder dysfunctions, neurogenic bladder, interstitial cystitis, urinary incontinence, premature ejaculation, inflammatory pain, peripherally mediated and neuropathic pain, cough, lung edema, diarrhea, cardiac disorders, cardioprotection, depression, and cognitive, respiratory, diarrhea, irritable bowel syndrome and gastro-intestinal disorders, immunomodulation, and anti-tumor agents.
    Type: Grant
    Filed: December 4, 2012
    Date of Patent: May 26, 2015
    Assignee: Alkermes, Inc.
    Inventors: Derrick Arnelle, Daniel Deaver, Reginald L. Dean, III, Mark Todtenkopf
  • Publication number: 20150094325
    Abstract: The instant application relates to morphinan derivatives of formula I with enhanced oral bioavailability for the treatment of diseases associated with opioid receptor activity or blockade including alcohol and opiate addiction.
    Type: Application
    Filed: October 6, 2014
    Publication date: April 2, 2015
    Inventors: Ryan Turncliff, Daniel Deaver, Derrick Arnelle
  • Patent number: 8962646
    Abstract: The invention relates to a compound of Formula I, II, III, IV or a pharmaceutically acceptable ester or prodrug thereof:
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: February 24, 2015
    Assignee: Alkermes, Inc.
    Inventors: Laura Cook Blumberg, Derrick Arnelle
  • Patent number: 8354534
    Abstract: The present invention relates to compounds of Formula I or II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which relates to morphinan compounds useful as ?, ?, and/or ? receptor opioid compounds and pharmaceuticals containing same that may be useful for mediating analgesia, combating drug addiction, alcohol addiction, drug overdose, mental illness, bladder dysfunctions, neurogenic bladder, interstitial cystitis, urinary incontinence, premature ejaculation, inflammatory pain, peripherally mediated and neuropathic pain, cough, lung edema, diarrhea, cardiac disorders, cardioprotection, depression, and cognitive, respiratory, diarrhea, irritable bowel syndrome and gastro-intestinal disorders, immunomodulation, and anti-tumor agents.
    Type: Grant
    Filed: February 13, 2009
    Date of Patent: January 15, 2013
    Assignee: Alkermes, Inc.
    Inventors: Derrick Arnelle, Daniel Deaver, Reginald L. Dean, III, Mark Todtenkopf
  • Publication number: 20130005755
    Abstract: The invention relates to a compound of Formula I, II, III, IV or a pharmaceutically acceptable ester or prodrug thereof:
    Type: Application
    Filed: June 29, 2012
    Publication date: January 3, 2013
    Inventors: Laura Cook Blumberg, Derrick Arnelle
  • Publication number: 20100240691
    Abstract: The instant application relates to morphinan derivatives of formula I with enhanced oral bioavailability for the treatment of diseases associated with opioid receptor activity or blockade including alcohol and opiate addiction.
    Type: Application
    Filed: March 19, 2010
    Publication date: September 23, 2010
    Applicant: Alkermes, Inc.
    Inventors: Ryan Turncliff, Daniel Deaver, Derrick Arnelle
  • Publication number: 20090209569
    Abstract: The present invention relates to compounds of Formula I or II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which relates to morphinan compounds useful as ?, ?, and/or ? receptor opioid compounds and pharmaceuticals containing same that may be useful for mediating analgesia, combating drug addiction, alcohol addiction, drug overdose, mental illness, bladder dysfunctions, neurogenic bladder, interstitial cystitis, urinary incontinence, premature ejaculation, inflammatory pain, peripherally mediated and neuropathic pain, cough, lung edema, diarrhea, cardiac disorders, cardioprotection, depression, and cognitive, respiratory, diarrhea, irritable bowel syndrome and gastro-intestinal disorders, immunomodulation, and anti-tumor agents.
    Type: Application
    Filed: February 13, 2009
    Publication date: August 20, 2009
    Applicant: Alkermes, Inc.
    Inventors: Derrick Arnelle, Daniel Deaver, Reginald L. Dean, III, Mark Todtenkopf